Dishman Carbogen Amcis (DCAL) Fundamentals 2026 — P/E 30.0x, Revenue Analysis | SniperIQ
Dishman Carbogen Amcis (DCAL) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹2,919 Crore, trading at ₹186.18 on the NSE. This SniperIQ fundamentals page covers Dishman Carbogen Amcis's valuation (P/E 30.0x, P/B 0.4x), profitability (net margin 3.3%), revenue (₹2,932 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dishman Carbogen Amcis's market cap?
Dishman Carbogen Amcis (DCAL) has a market capitalization of approximately ₹2,919 Crore, trading at ₹186.18 on the NSE. Market cap moves with the live share price.
What is Dishman Carbogen Amcis's P/E ratio?
Dishman Carbogen Amcis's trailing twelve-month P/E ratio is 30.0x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dishman Carbogen Amcis?
Dishman Carbogen Amcis runs a net profit margin of 3.3%, a gross margin of 39.9%, and an operating margin of 7.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dishman Carbogen Amcis generate?
Dishman Carbogen Amcis reported revenue of ₹2,932 Crore for fiscal year 2026, with net income of ₹97 Crore and earnings per share (EPS) of 6.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dishman Carbogen Amcis pay a dividend?
Dishman Carbogen Amcis does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Dishman Carbogen Amcis financially healthy?
Dishman Carbogen Amcis carries a debt-to-equity ratio of 0.46x and a current ratio of 1.23x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dishman Carbogen Amcis a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dishman Carbogen Amcis (DCAL) the key facts are: market cap ₹2,919 Crore, P/E 30.0x, revenue ₹2,932 Crore, 52-week range 128.5-321.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dishman Carbogen Amcis's full fundamentals live
Get Dishman Carbogen Amcis's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.